Belite Bio Insider Sell‑Off: What Investors Need to Know – Is Confidence at Stake?
Insider selling at Belite Bio: CEO’s 383‑share exit shows rebalancing, not panic, while the firm’s growth pipeline and recent earnings beat keep a “Buy” outlook.
3 minutes to read